Show simple item record

dc.contributor.authorBivins, Ashley
dc.contributor.authorHou, Karolyn
dc.contributor.authorAyesu, Nana
dc.contributor.authorEllsworth, Brian, Jr.
dc.contributor.authorMontenegro, Susan
dc.contributor.authorTu, Xiao
dc.contributor.authorDowling, Thomas C.
dc.contributor.authorShaya, Fadia T.
dc.contributor.authorBoyle, Cynthia J.en_US
dc.date.accessioned2011-11-16T18:14:58Z
dc.date.available2011-11-16T18:14:58Z
dc.date.issued2010
dc.identifier.citationBivins, A., Hou, K., Ayesu, N., Ellsworth, B., Montenegro, S., Tu, X., Boyle, C., Dowling, T. C., & Shaya, F. T. (2010). Clinical evaluation of natalizumab for formulary consideration. Expert Opinion on Biological Therapy, 10(8), 1279-1287.en_US
dc.identifier.issn1471-2598
dc.identifier.urihttp://hdl.handle.net/10713/692
dc.description.abstractImportance of the field: Natalizumab is a monotherapy for relapsing forms of multiple sclerosis (MS) and maintaining remission in Crohn’s disease (CD). Evaluation of natalizumab’s clinical relevance must be performed before considering its place in treatment of these diseases. Areas covered in this review: MEDLINE and PubMed searches were performed using the keywords multiple sclerosis, Crohn’s disease, natalizumab and clinical trials. The manufacturer’s product information was consulted to extract additional data. Pivotal clinical trials included: Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM), Safety and Efficacy of Natalizumab in Combination With Interferon Beta-1a in Patients With Relapsing Remitting Multiple Sclerosis (SENTINEL), Efficacy of Natalizumab as Active Crohn’s Therapy (ENACT)-1 and 2 and Efficacy of Natalizumab in Crohn’s Disease Response and Remission (ENCORE). What the reader will gain: AFFIRM and SENTINEL showed improvements in progression of MS. ENACT-1 failed to show a significant effect, but the follow-up trials ENACT-2 and ENCORE were able to demonstrate a response to natalizumab. Take home message: Two trials on efficacy of Tysabri for treatment of MS demonstrated positive results. Efficacy for CD was mixed. More research demonstrating head-to-head evidence against other agents is necessary to determine if Tysabri’s benefits are significant.en_US
dc.language.isoen_USen_US
dc.publisherUK: Ashley Publications Ltden_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectcomparative effectivenessen_US
dc.subjectTysabrien_US
dc.subject.meshCrohn Diseaseen_US
dc.subject.meshMultiple Sclerosisen_US
dc.subject.meshNatalizumaben_US
dc.titleClinical evaluation of natalizumab for formulary considerationen_US
dc.typeArticleen_US
refterms.dateFOA2019-02-19T17:16:09Z


Files in this item

Thumbnail
Name:
Clinical evaluation of natalizumab ...
Size:
297.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/